2018 ACR/ARHP Annual Meeting

October 19-24, 2018. Chicago, IL.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2257

Prevalence and Distinct Clinical Phenotype of Concomitant Sarcoidosis in Other Autoimmune Rheumatic Diseases
Abstract Number: 664

Prevalence and Factors Associated with Peripheral Manifestations in Spondyloarthritis. an Ancillary Analysis of the ASAS-Comospa Study
Abstract Number: 2148

Prevalence and Incidence of FMF in Germany – Results of the First Retrospective Analysis of Representative Claims Data
Abstract Number: 2163

Prevalence and Incidence of Idiopathic Inflammatory Myopathies in Korea:a Nationwide Population-Based Study over 10 Years
Abstract Number: 752

Prevalence and Predictors of Peripheral Vascular Disease in a Cohort of Systemic Lupus Erythematosus (SLE) Patients
Abstract Number: 1566

Prevalence and Prognosis of Interstitial Lung Disease in a Large Cohort of Chinese Primary Sjögren’s Syndrome Patients
Abstract Number: 536

Prevalence and Relative Factors for Frailty in Patients with RA from a Prospective Observational Study
Abstract Number: 2449

Prevalence and Risk Factors of Serious Infections in Rheumatoid Arthritis Patients Receiving the Biologic/Targeted Synthetic Dmards: A Propensity Score Analysis from the Hong Kong Biologics Registry
Abstract Number: 2118

Prevalence of Acquired Activated Protein C Resistance and Anti-Protein C Antibodies in Systemic Lupus Erythematosus
Abstract Number: 1605

Prevalence of Anterior Uveitis in Patients with Spondyloarthropathy in a Single US Academic Center: A Retrospective Study from Routine Care
Abstract Number: 259

Prevalence of Attention Deficit Hyperactivity Disorder Among Patients with Fibromyalgia
Abstract Number: 2649

Prevalence of Cancer in Systemic Lupus Erythematosus
Abstract Number: 705

Prevalence of Cervical Human Papillomavirus Infection in Women with Systemic Lupus Erythematosus: A Systematic Review and Meta-Analysis
Abstract Number: 2727

Prevalence of Clinical and Subclinical Ophthalmologic Manifestations in Association with Systemic Symptoms, Disease Activity and Damage in Patients with Granulomatosis with Polyangiitis
Abstract Number: 804

Prevalence of Echocardiographic Abnormalities in Patients with Systemic Sclerosis

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].